Retinal degeneration arises from the loss of photoreceptors or retinal pigment epithelium (RPE). It is one of the leading causes of irreversible blindness worldwide with limited effective treatment options. Generation of stem cell-derived retinal cells and tissues from individuals with retinal degeneration is a rapidly evolving technology that holds a great potential for its use in disease modelling. Stem cell technology provides an ideal platform to investigate normal and pathological retinogenesis, but also delivers a valuable source of retinal cell types for drug screening and cell therapy.
Application of patient specific stem cells for disease modelling, drug discovery, gene therapy, small molecule screening and cell transplantation.
Stem cells, especially IPSCs, have been used to model diseases of the outer retina including retinitis pigmentosa (RP), Usher syndrome (USH), Leber congenital amaurosis (LCA), gyrate atrophy (GA), juvenile neuronal ceroid lipofuscinosis (NCL), Best vitelliform macular dystrophy (BVMD) and age-related macular degeneration (AMD).
Safety Assessment of hiPSC-Derived Retinal Cells.
Comprehensive characterization and quality control services for disease-specific models are available by BioCytoceuticals.
BioCytoceuticals leads the industry in cellular therapy with commitment to providing the most appropriate solutions to address the needs of our clients. Our expert team of scientists applies comprehensive methods and the most detail-oriented scrutiny to ensure only top-tier outcome is submitted.
If you have any special enquiries regarding our Retinal Disease models service, please do not hesitate to contact us. Our highly professional technical supporting staffs will make sure your requests are faithfully received. We are looking forward to earning your business.
Inquiry
